No Data
The "DeepSeek Moment" of medicine, has China’s Innovative Drugs also reached it?
Over the past four years, China's share of Global large-scale pharmaceutical Trade has surged from 5% to 30%. From research and development innovation to international mergers and acquisitions, Chinese Innovative Drugs companies are reshaping the Global pharmaceutical innovation landscape.
Genor Biopharma Holdings Postpones EGM to February 19
Genor Biopharma Proposes to Replace Auditor
GENOR-B (06998) intends to appoint Ernst & Young as the new auditor.
GENOR-B (06998) announced that the company plans to pass the resolution at the special Shareholder meeting to be held.
Hong Kong stocks movement | GENOR-B (06998) rises nearly 10% against the market, recently announced a strategic merger agreement with Eton Pharmaceuticals.
GENOR-B (06998) rose nearly 10% against the market trend. As of the time of writing, it has increased by 9.83%, trading at 1.9 Hong Kong dollars, with a transaction amount of 1.8356 million Hong Kong dollars.
Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.
① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.
